Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMTS1215 in Solid Tumors
NCT07556276Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- Mar 2025
- Primary completion
- Dec 2030
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CMTS1215 in solid tumor, sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoints: Objective Response Rate at 4 weeks and Treatment-Emergent Adverse Events at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
CMTS1215
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07556276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556276.